2117 SW HIGHWAY 484, OCALA, FL
AIM ImmunoTech Inc. Enters Into Exchange Agreements for $1.22M Debt
Is Force Protection: Ready Today, Prepared for Tomorrow
Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
AIM ImmunoTech Enters $1.5 Million Proposal Agreement with Sterling Pharma
Termination of Equity Distribution Agreement with Maxim Group LLC
Shareholder votes
Regains NYSE American Compliance
Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
Q2
Q1
FY 2025
Notice of Late Filing for Quarterly Report
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Definitive Additional Information Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload